A disintegrin and metalloproteinase 17 (ADAM17) mediates epidermal growth factor receptor transactivation by angiotensin II on hepatic stellate cells

详细信息    查看全文

• 作者：Hiroki Oikawa ; Chihaya Maesawa ; Yoshinori Tatemichi ; Yutaka Nishinari ; Masao Nishiya ; Hisata Mizugai ; Aya Ikeda ; Kanta Oikawa ; Yasuhiro Takikawa ; Tomoyuki Masuda
• 关键词：EGFR transactivation ; Angiotensin II ; ADAM17 ; Amphiregulin ; Hepatic stellate cell
• 刊名：Life Sciences
• 出版年：3 March, 2014
• 年：2014
• 卷：97
• 期：2
• 页码：137-144
• 全文大小：489 K

文摘

Aims

Epidermal growth factor receptor (EGFR) transactivation induced by angiotensin II (Ang II) participates in the progression of various diseases. A disintegrin and metalloproteinase 17 (ADAM17) is thought to promote renal fibrosis, cardiac hypertrophy with fibrosis and atherosclerosis by activation of the EGFR through secretion of EGFR ligands. The purpose of this study was to investigate whether Ang II-induced EGFR transactivation occurs on hepatic stellate cells (HSCs) and whether the reaction is mediated via ADAM17.

Main methods

Ang II-induced EGFR transactivation and cellular proliferation of the human HSC line LI90 were investigated using Western blotting and ATP assay, respectively. Ang II-induced secretion of mature amphiregulin into the cell culture medium was evaluated by enzyme-linked immunosorbent assay (ELISA).

Key findings

An inhibitor of ADAM17, TAPI-1, as well as antagonists of EGFR and angiotensin II type-1 receptor (AT1), attenuated Ang II-induced EGFR transactivation and proliferation of LI90 cells. Furthermore, silencing of ADAM17 inhibited Ang II-induced secretion of mature amphiregulin in addition to EGFR transactivation.

Significance

These results indicate that ADAM17 mediates Ang II-induced EGFR transactivation on HSCs, and that this process may participate in the progression of liver fibrosis.